Last updated on May 2019

IACS-010759 in Advanced Cancers


Brief description of study

This phase I trial studies the side effects and best dose of oxidative phosphorylation inhibitor IACS-010759 (IACS-010759) in treating participants with lymphoma that has come back or does not respond to treatment or solid tumors that have spread to other places in the body or cannot be removed by surgery. IACS-010759 may stop the growth of cancer or tumor cells by blocking some of the enzymes needed for cell growth.

Detailed Study Description

PRIMARY OBJECTIVES:

I. To determine the safety and tolerability of IACS-010759, the maximum tolerated dose (MTD) and recommended phase 2 dose (RP2D) in subjects with any advanced solid tumor and lymphoma.

SECONDARY OBJECTIVES:

I. To evaluate IACS-010759 pharmacokinetics and preliminary antitumor activity (including overall response rate and duration of response).

EXPLORATORY OBJECTIVES:

I. To evaluate pharmacodynamic and exploratory predictive biomarkers of activity of IACS-010759.

OUTLINE: This is a dose-escalation study.

INDUCTION PHASE: Participants receive oxidative phosphorylation inhibitor IACS-010759 orally (PO) once daily (QD) on days 1-7 of course 1 in the absence of disease progression or unacceptable toxicity.

MAINTENANCE PHASE: Participants receive oxidative phosphorylation inhibitor IACS-010759 PO QD on days 8 and 15 of course 1 and then on days 1, 8, and 15 of subsequent courses. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.

After completion of study treatment, participants are followed up at 30 days and then every 3-6 months for up to 2 years.

Clinical Study Identifier: NCT03291938

Find a site near you

Start Over

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.